X4 Pharmaceuticals, Inc (XFOR) — SEC Financial Statements & Analysis

X4 Pharmaceuticals, Inc (XFOR) is a biological products, (no diagnostic substances) company, incorporated in DE. X4 Pharmaceuticals, Inc trades on Nasdaq as: XFOR. X4 Pharmaceuticals, Inc (XFOR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, X4 Pharmaceuticals, Inc carries a market cap of $590.03M, a P/E ratio of -6.55x, a P/B ratio of 3.80x, a P/S ratio of 37.23x, an enterprise value of $394.26M, and an EV/EBITDA multiple of -4.57x. On profitability, it posts a gross margin of 81.51%, an operating margin of -554.71%, a net margin of -568.80%, a Return on Equity (ROE) of -113.08%, a Return on Assets (ROA) of -50.32%, and a Return on Invested Capital (ROIC) of -201.20%. Per share, it reports EPS of $-0.71, diluted EPS of $-0.71, free cash flow per share of $-0.66, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -51.65% year-over-year, net income growth of -11.61% year-over-year, and EPS growth of -94.81% year-over-year. On the balance sheet, it maintains a current ratio of 11.30x, a quick ratio of 10.84x, working capital of $199.49M, a debt-to-equity ratio of 0.63x, a debt ratio of 0.39, an interest coverage ratio of -10.06x, free cash flow of $-83.74M (TTM), and net debt of $-195.77M. Figures sourced from SEC EDGAR.

Market Cap

$590.03M

P/E TTM

-6.55x

EPS TTM

$-0.71

P/B TTM

3.80x

ROE TTM

-113.08%

ROA TTM

-50.32%

Debt To Equity

0.63x

Free Cash Flow TTM

$-83.74M

Net Revenue TTM Growth 1Y

-51.65%

Data as of 2026-06-30 · Source: SEC EDGAR